LPAR2

Receptor lizofosfatidne kiseline 2
Identifikatori
Simboli LPAR2; EDG-4; EDG4; LPA-2; LPA2
Vanjski ID OMIM: 605110 MGI: 1858422 HomoloGene: 3465 IUPHAR: LPA2 GeneCards: LPAR2 Gene
Ontologija gena
Molekularna funkcija • vezivanje G-protein alfa podjedinice
• aktivnost G-protein spregnutog receptora
• proteinsko vezivanje
• vezivanje PDZ domena
• veivanje LIM domena
Celularna komponenta • citoplazma
• ćelijska membrana
• integralno sa ćelijskom membranom
• ćelijska površina
Biološki proces • activacija MAPK aktivnosti
• signalni put G-protein spregnutog receptora
• aktivacija fosfolipaze C
• povišenje koncentracije citozolnih jona kalcijuma
Pregled RNK izražavanja
podaci
Ortolozi
Vrsta Čovek Miš
Entrez 9170 53978
Ensembl ENSG00000064547 ENSMUSG00000031861
UniProt Q9HBW0 E9QJW6
RefSeq (mRNA) NM_004720.5 NM_020028.3
RefSeq (protein) NP_004711.2 NP_064412.2
Lokacija (UCSC) Chr 19:
19.73 - 19.74 Mb		 Chr 8:
72.35 - 72.36 Mb
PubMed pretraga [1] [2]

Receptor lizofosfatidne kiseline 2 (LPA2) je protein koji je kod ljudi kodiran LPAR2 genom.[1][2][3] LPA2 je G protein spregnuti receptor za koji se vezuje lipidni signalni molekul lizofosfatidna kiselina (LPA).[4]

Funkcija

Ovaj protein je član familije I G protein spregnutih receptora, kao i EDG familije. Ovaj protein funkcioniše kao receptor lizofosfatidne kiseline i doprinosi mobilizaciji Ca2+. To je kritični ćelijski respons na LPA, putem asocijacije sa Gi i Gq proteinima.[1]

Interakcije

LPAR2 formira interakcije sa TRIP6.[5]

Reference

  1. ^ а б „Entrez Gene: LPAR2 Lysophosphatidic acid receptor 2”. 
  2. ^ An S, Bleu T, Hallmark OG, Goetzl EJ (1998). „Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid”. J. Biol. Chem. 273 (14): 7906—10. PMID 9525886. doi:10.1074/jbc.273.14.7906. 
  3. ^ An S, Bleu T, Zheng Y, Goetzl EJ (1998). „Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization”. Mol. Pharmacol. 54 (5): 881—8. PMID 9804623. 
  4. ^ Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, Chun J (2010). „LPA Receptors: Subtypes and Biological Actions”. Annual Review of Pharmacology and Toxicology. 50 (1): 157—186. PMID 20055701. doi:10.1146/annurev.pharmtox.010909.105753. 
  5. ^ Xu, Jun; Lai Yun-Ju; Lin Weei-Chin; Lin Fang-Tsyr (2004). „TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor”. J. Biol. Chem. United States. 279 (11): 10459—68. ISSN 0021-9258. PMID 14688263. doi:10.1074/jbc.M311891200. 

Literatura

  • Spiegel, S. (2000). „Sphingosine 1-phosphate: a ligand for the EDG-1 family of G-protein-coupled receptors.”. Ann. N. Y. Acad. Sci. 905: 54—60. PMID 10818441. doi:10.1111/j.1749-6632.2000.tb06537.x. 
  • Contos JJ, Ishii I, Chun J (2001). „Lysophosphatidic acid receptors.”. Mol. Pharmacol. 58 (6): 1188—96. PMID 11093753. 
  • Goetzl, E. J.; Dolezalova, H.; Y, Kong; et al. (1999). „Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer.”. Cancer Res. 59 (20): 5370—5. PMID 10537322. 
  • Contos JJ, Chun J (2000). „Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA.”. Genomics. 64 (2): 155—69. PMID 10729222. doi:10.1006/geno.2000.6122. 
  • Bandoh, K.; J, Aoki; Taira, A.; et al. (2000). „Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors.”. FEBS Lett. 478 (1–2): 159—65. PMID 10922489. doi:10.1016/S0014-5793(00)01827-5. 
  • Young, K. W.; Bootman, M. D.; Channing, D. R.; et al. (2001). „Lysophosphatidic acid-induced Ca2+ mobilization requires intracellular sphingosine 1-phosphate production. Potential involvement of endogenous EDG-4 receptors.”. J. Biol. Chem. 275 (49): 38532—9. PMID 10954727. doi:10.1074/jbc.M006631200. 
  • Zheng Y, Voice JK, Kong Y, Goetzl EJ (2001). „Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes.”. FASEB J. 14 (15): 2387—9. PMID 11024010. doi:10.1096/fj.00-0492fje. 
  • Hama, K.; K, Bandoh; Kakehi, Y.; et al. (2002). „Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors.”. FEBS Lett. 523 (1–3): 187—92. PMID 12123830. doi:10.1016/S0014-5793(02)02976-9. 
  • Strausberg, R. L.; Feingold, E. A.; Grouse, L. H.; et al. (2003). „Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899—903. PMC 139241 Слободан приступ. PMID 12477932. doi:10.1073/pnas.242603899. 
  • Fujita, T.; S, Miyamoto; Onoyama, I.; et al. (2003). „Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer.”. Cancer Lett. 192 (2): 161—9. PMID 12668280. doi:10.1016/S0304-3835(02)00713-9. 
  • Hu YL, Albanese C, Pestell RG, Jaffe RB (2003). „Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells.”. J. Natl. Cancer Inst. 95 (10): 733—40. PMID 12759391. doi:10.1093/jnci/95.10.733. 
  • Xu J, Lai YJ, Lin WC, Lin FT (2004). „TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor.”. J. Biol. Chem. 279 (11): 10459—68. PMID 14688263. doi:10.1074/jbc.M311891200. 
  • Ota, T.; Y, Suzuki; Nishikawa, T.; et al. (2004). „Complete sequencing and characterization of 21,243 full-length human cDNAs.”. Nat. Genet. 36 (1): 40—5. PMID 14702039. doi:10.1038/ng1285. 
  • Grimwood, J.; Gordon, L. A.; Olsen, A.; et al. (2004). „The DNA sequence and biology of human chromosome 19.”. Nature. 428 (6982): 529—35. PMID 15057824. doi:10.1038/nature02399. 
  • Oh, Y. S.; Jo, N. W.; Choi, J. W.; et al. (2004). „NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation.”. Mol. Cell. Biol. 24 (11): 5069—79. PMC 416407 Слободан приступ. PMID 15143197. doi:10.1128/MCB.24.11.5069-5079.2004. 
  • Gerhard, D. S.; Wagner, L.; Feingold, E. A.; et al. (2004). „The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).”. Genome Res. 14 (10B): 2121—7. PMC 528928 Слободан приступ. PMID 15489334. doi:10.1101/gr.2596504. 

Vidi još

Spoljašnje veze

  • „Lysophospholipid Receptors: LPA2”. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Архивирано из оригинала 03. 03. 2016. г. 
  • Lysophospholipid+receptors на US National Library of Medicine Medical Subject Headings (MeSH)
  • п
  • р
  • у
Klasa A: Rodopsinu slični
Neurotransmiter
Adrenergički
α1 (A, B, D) • α2 (A, B, C) • β1 • β2 • β3
Purinski
Adenozinski (A1, A2A, A2B, A3) • P2Y (1, 2, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14)
Serotoninski
(svi osim 5-HT3) 5-HT1 (A, B, D, E, F) • 5-HT2 (A, B, C) • 5-HT (4, 5A, 6, 7)
Drugi
Acetilholin (M1, M2, M3, M4, M5) • Dopamin (D1, D2, D3, D4, D5) • Histamin (H1, H2, H3, H4) • Melatonin (1A, 1B, 1C) • TAAR (1, 2, 3, 5, 6, 8, 9)
Metaboliti i
signalni molekuli
Eikozanoidni
CysLT (1, 2) • LTB4 (1, 2) • FPRL1 • OXE • Prostaglandin (DP (1, 2), EP (1, 2, 3, 4), FP) • Prostaciklin • Tromboksan
Drugi
Žučna kiselina • Kanabinoidni (CB1, CB2, GPR (18, 55, 119)) • EBI2 • Estrogen • Slobodna masna kiselina (1, 2, 3, 4) • Laktat • Lizofosfatidna kiselina (1, 2, 3, 4, 5, 6) • Lizofosfolipid (1, 2, 3, 4, 5, 6, 7, 8) • Niacin (1, 2) • Oksoglutarat • PAF • Sfingozin-1-fosfat (1, 2, 3, 4, 5) • Sukcinat
Peptid
Neuropeptidni
B/W (1, 2) • FF (1, 2) • S • Y (1, 2, 4, 5) • Neuromedin (B, U (1, 2)) • Neurotenzin (1, 2)
Drugi
Anafilatoksin (C3a, C5a) • Angiotenzin (1, 2) • Apelin • Bombezin (BRS3, GRPR, NMBR) • Bradikinin (B1, B2) • Hemokin • Holecistokinin (A, B) • Endotelin (A, B) • Formil peptid (1, 2, 3) • FSH • Galanin (1, 2, 3) • GHB receptor • Gonadotropin-oslobađajući hormon (1, 2) • Grelin • Kispeptin • Luteinizirajući hormon/horiogonadotropin • MAS (1, 1L, D, E, F, G, X1, X2, X3, X4) • Melanokortin (1, 2, 3, 4, 5) • MCHR (1, 2) • Motilin • Opioidni (δ, κ, μ, Nociceptin & ζ, ali ne σ) • Oreksin (1, 2) • Oksitocin • Prokineticin (1, 2) • Prolaktin-oslobađajući peptid • Relaksin (1, 2, 3, 4) • Somatostatin (1, 2, 3, 4, 5) • Tahikinin (1, 2, 3) • Tirotropin • Tirotropin-oslobađajući hormon • Urotenzin-II • Vazopresin (1A, 1B, 2)
Razno
Orfan
GPR (1, 3, 4, 6, 12, 15, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 31, 32, 33, 34, 35, 37, 39, 42, 44, 45, 50, 52, 55, 61, 62, 63, 65, 68, 75, 77, 78, 81, 82, 83, 84, 85, 87, 88, 92, 101, 103, 109A, 109B, 119, 120, 132, 135, 137B, 139, 141, 142, 146, 148, 149, 150, 151, 152, 153, 160, 161, 162, 171, 173, 174, 176, 177, 182, 183)
Drugi
Adrenomedulin • Mirisni • Opsin (3, 4, 5, 1LW, 1MW, 1SW, RGR, RRH) • Proteazom-aktivirani (1, 2, 3, 4) • SREB (1, 2, 3)
Klasa B: Sekretinu slični
Orfan
GPR (56, 64, 97, 98, 110, 111, 112, 113, 114, 115, 116, 123, 124, 125, 126, 128, 133, 143, 144, 155, 157)
Drugi
Klasa C: Metabotropni
glutamat / feromon
Ukus
TAS1R (1, 2, 3) • TAS2R (1, 3, 4, 5, 8, 9, 10, 12, 13, 14, 16, 19, 20, 30, 31, 38, 39, 40, 41, 42, 43, 45, 46, 50)
Drugi
Kalcijum-detektujući receptor • GABA B (1, 2) • Glutamatni receptor (Metabotropni glutamat (1, 2, 3, 4, 5, 6, 7, 8)) • GPRC6A • GPR (156, 158, 179) • RAIG (1, 2, 3, 4) • VNR (1, 2, 3, 5)
Klasa F:
Frizzled / Zaglađeni
Uvojiti
Frizzled (1, 2, 3, 4, 5, 6, 7, 8, 9, 10)
Zaglađeni